Protocol Ledger

NCT03969420 · Phase II · TERMINATED

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

Interventional Phase II clinical trial protocol NCT03969420 sponsored by Sumitomo Pharma America in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-15 Enrollment: 11 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03969420
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)11 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03969420
Protocol FieldVerified Registry Value
NCT IdentifierNCT03969420
Consolidated Lead SponsorSumitomo Pharma America
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment11 participants (ACTUAL)
Registered Start Date2020-01-15
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI